Filing Details

Accession Number:
0001062993-23-022638
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-15 16:38:12
Reporting Period:
2023-12-15
Accepted Time:
2023-12-15 16:38:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1042074 Cymabay Therapeutics Inc. CBAY Pharmaceutical Preparations (2834) 943103561
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1705745 Daniel Menold C/O Cymabay Therapeutics, Inc.
7575 Gateway Blvd., Suite 110
Newark CA 94560
Vice President, Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-15 10,000 $4.05 10,000 No 4 M Direct
Common Stock Disposition 2023-12-15 10,000 $21.98 0 No 4 S Direct
Common Stock Acquisiton 2023-12-15 11,497 $8.43 11,497 No 4 M Direct
Common Stock Disposition 2023-12-15 11,497 $21.99 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2023-12-15 10,000 $0.00 10,000 $4.05
Common Stock Employee Stock Option (right to buy) Disposition 2023-12-15 11,497 $0.00 11,497 $8.43
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
145,109 2030-05-14 No 4 M Direct
0 2029-01-28 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.70 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The shares subject to the option vest in 48 equal monthly installments commencing on January 31, 2020.
  5. The shares subject to the option vest as to 1/4 of the underlying shares on January 1, 2020, and vest as to 1/48 of the underlying shares monthly thereafter.